What happened with WAY today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Waystar Holding Corp. supplies software that helps healthcare providers get paid by insurers and patients. It connects steps from checking coverage and estimating patient costs to submitting insurance claims, resolving denied claims and collecting patient bills. Its AltitudeAI engine uses transaction and clinical data to help identify missing charges and prepare corrections, among other tasks.
Providers pay Waystar mainly through recurring subscriptions and fees tied to transaction volumes. Subscription fees provide a fixed revenue stream, while usage-based fees rise as clients treat more patients and use more services. Most revenue comes from outpatient and other non-hospital care settings, with hospitals and health systems supplying the rest. Its client base is diversified rather than dependent on one large customer. The business depends on clients renewing contracts, buying additional solutions and continuing to process healthcare transactions through its platform.
Waystar connects with insurers and integrates with providers’ electronic health record and practice-management systems, making those relationships important to service delivery. Healthcare privacy laws and client permissions limit how it can use patient data. Training its AI on de-identified claims data requires explicit client rights and permissions and compliance with HIPAA de-identification requirements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Waystar’s results hinge on healthcare transaction volumes and providers’ adoption of payment automation; watch Optum, Epic and Athena as important competing alternatives outside this list.
Phreesia, Inc. competes with Waystar for healthcare providers buying software and payment services to collect patients’ payments, with overlap in workflows for accessing care. Watch Phreesia’s payment-processing and financing fee revenue for a read on the patient-payment business where they overlap.
Solventum competes with Waystar through software that helps healthcare providers code care, automate reimbursement and capture revenue from clinical services. Watch its Health Information Systems business rather than total sales: that business accounted for 16.3% of Solventum’s sales in 2025, while it also sells medical and dental products.
Fed Interest Rate Decision
Waystar’s variable-rate debt, including its $80 million receivables-facility borrowing priced at SOFR plus 1.61%, can cost more when interest rates rise, reducing earnings.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets a higher policy rate than expected, Waystar may pay more interest on debt that reprices, leaving less earnings after debt costs.
If it comes in below expectations
If the Fed sets a lower policy rate than expected, interest costs on debt that reprices may ease, leaving more earnings after debt costs.
Waystar Holding Corp. earningsThis company
Waystar's report will show whether provider subscriptions and transaction-based fees are growing enough to lift net income after operating costs.
Read revenue alongside net income. If both rise, growth in subscriptions and healthcare transactions is reaching the bottom line after operating costs. If revenue rises but net income stalls or falls, costs are absorbing the gains, and Waystar is not yet turning that growth into more profit.
Solventum Corporation earningsSOLV
Solventum's Health Information Systems results show whether providers are spending on coding and revenue-management software in the market where Waystar competes.
Focus on Health Information Systems sales, not Solventum's total sales; the business accounted for 16.3% of sales in 2025. Growth would show that provider spending on coding, reimbursement and revenue-management software is holding up, in a market where Waystar also competes. A decline while other Solventum businesses support total sales would point to softness in this software area, not prove that Waystar is losing customers.
Phreesia, Inc. earningsPHR
Phreesia's payment-processing and financing fees offer a read on patient-payment services that overlap with Waystar's business.
Watch Phreesia's payment-processing and financing fee revenue, rather than total revenue. Growth would suggest activity is holding up in the patient-payment services the companies share, a supportive sign for Waystar's market. A decline would flag softness in that area, but would not by itself prove that Waystar's own transactions or client base are shrinking.
